PCDH11Y

Across TCGA pan-cancer cohorts, PCDH11Y Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PCDH11Y data layer compared with 20 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PCDH11Y Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDH11Y expression acts as an unfavorable survival marker.

LIHC, SCLC, and ESCA are the cancer types where PCDH11Y Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	III,IV	0.092	0.649	<.001	18	view →
SCLC	DFS	Median	All	0.204	0.508	.025	6	view →
ESCA	DFS	Median	All	0.195	0.535	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PCDH11Y–LIHC (OS)

Open the LIHC breakdown →